Adamas Pharmaceuticals Inc Business Finance Contracts & Agreements
21 Contracts & Agreements
- Assignment Agreements (1 contract)
- Investor Rights Agreements (1)
- Loan Agreements (3)
- Note Agreements (2)
- Purchase Agreements (2)
- Stock Agreements (6)
- Term Sheets (2)
- Underwriting Agreements (4)
- First Amendment to Asset Purchase Agreement by and between Adamas Pharmaceuticals, Inc. and Osmotica Pharmaceutical US LLC (Filed With SEC on August 9, 2021)
- Binding Term Sheet by and between Adamas Pharma, LLC and Zydus Worldwide DMCC and Zydus Pharmaceuticals (USA) Inc (Filed With SEC on May 10, 2021)
- Underwriting Agreement, dated February 24, 2021, by and between the Company and SVB Leerink LLC and William Blair & Company, L.L.C., as representatives of the underwriters named... (Filed With SEC on February 25, 2021)
- Amendment No. 3 to the Loan Agreement dated December 1, 2020 between Adamas Pharma, LLC and Healthcare Royalty Partners III, L.P (Filed With SEC on February 23, 2021)
- Asset Purchase Agreement by and between Adamas Pharmaceuticals, Inc. and Osmotica Pharmaceutical US LLC (Filed With SEC on February 23, 2021)
- Binding Term Sheet by and between Adamas Pharma, LLC and Sandoz, Inc (Filed With SEC on February 25, 2020)
- Amendment No. 2 to the Loan Agreement dated January 2, 2020 between Adamas Pharma, LLC and Healthcare Royalty Partners III, L.P (Filed With SEC on February 25, 2020)
- Description of Capital Stock (Filed With SEC on February 25, 2020)
- Secured Promissory Note dated November 27, 2017 between Adamas Pharma, LLC and Healthcare Royalty Partners III, L.P (Filed With SEC on February 22, 2018)
- Underwriting Agreement, dated January 23, 2018, by and among the Company and Merrill Lynch, Pierce, Fenner & Smith Incorporated, Leerink Partners LLC, and Evercore Group L.L.C.,... (Filed With SEC on January 24, 2018)
- Secured Promissory Note dated May 11, 2017 between Adamas Pharma, LLC and Healthcare Royalty Partners III, L.P (Filed With SEC on August 8, 2017)
- Loan Agreement dated May 11, 2017 between Adamas Pharma, LLC and Healthcare Royalty Partners III, L.P (Filed With SEC on August 8, 2017)
- ADAMAS PHARMACEUTICALS, INC. $50,000,000 COMMON STOCK SALES AGREEMENT (Filed With SEC on May 11, 2017)
- 2,500,000 Shares ADAMAS PHARMACEUTICALS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on January 7, 2016)
- EXHIBIT A Confidential Information and Invention Assignment Agreement (Filed With SEC on August 13, 2014)
- ADAMAS PHARMACEUTICALS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 20, 2014 APPROVED BY THE STOCKHOLDERS: MARCH 23, 2014 (Filed With SEC on March 26, 2014)
- [] Shares Adamas Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on March 20, 2014)
- ADAMAS PHARMACEUTICALS, INC. FOURTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT June 30, 2011 (Filed With SEC on March 5, 2014)
- ADAMAS PHARMACEUTICALS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 20, 2014 APPROVED BY THE STOCKHOLDERS: , 2014 (Filed With SEC on March 5, 2014)
- ADAMAS PHARMACEUTICALS, INC. 2007 STOCK PLAN ADOPTED ON DECEMBER 12, 2007 AMENDED THROUGH SEPTEMBER 3, 2013 (Filed With SEC on March 5, 2014)
- NEUROMOLECULAR, INC. 2002 EMPLOYEE, DIRECTOR AND CONSULTANT STOCK PLAN (Filed With SEC on March 5, 2014)
